NASDAQ:VECT

VectivBio (VECT) Stock Forecast, Price & News

$16.55

0.00 (0.00%)

(As of 06/1/2023 ET)

Compare

Today's Range: $16.50
▼
$16.80
50-Day Range: $8.25
▼
$16.55
52-Week Range: $4.25
▼
$16.80

Volume: 976,363 shs
Average Volume: 434,072 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.33

VectivBio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 47.0% Upside
$24.33 Price Target
Short Interest: Healthy
2.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.22
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.80) to ($1.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
VectivBio has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.33, VectivBio has a forecasted upside of 47.0% from its current price of $16.55.
Amount of Analyst Coverage
VectivBio has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.09% of the float of VectivBio has been sold short.
Short Interest Ratio / Days to Cover
VectivBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VectivBio has recently increased by 123.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
VectivBio does not currently pay a dividend.
Dividend Growth
VectivBio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VECT.

2.9

News and Social Media Coverage

News Sentiment
VectivBio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for VectivBio this week, compared to 1 article on an average week.
Search Interest
6 people have searched for VECT on MarketBeat in the last 30 days.
MarketBeat Follows
9 people have added VectivBio to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VectivBio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of VectivBio is held by insiders.
Percentage Held by Institutions
90.52% of the stock of VectivBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for VectivBio are expected to decrease in the coming year, from ($1.80) to ($1.99) per share.
Price to Book Value per Share Ratio
VectivBio has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About VectivBio (NASDAQ:VECT) Stock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

VECT Stock News Headlines

May 31, 2023 | benzinga.com

Moore Kuehn Encourages VECT, EMBK, BACK, and RADI Investors to Contact Law Firm

May 28, 2023 | americanbankingnews.com

VectivBio (NASDAQ:VECT) & Kodiak Sciences (NASDAQ:KOD) Financial Review

June 1, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

May 25, 2023 | businesswire.com

VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG ...

May 25, 2023 | americanbankingnews.com

VectivBio (NASDAQ:VECT) Cut to "Neutral" at Credit Suisse Group

May 24, 2023 | msn.com

Piper Sandler Downgrades VectivBio Holding (VECT)

May 23, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About VectivBio Holding

May 23, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and VectivBio Holding (VECT)

June 1, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

May 23, 2023 | finance.yahoo.com

Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%

May 23, 2023 | msn.com

Credit Suisse Downgrades VectivBio Holding (VECT)

May 23, 2023 | msn.com

SVB Leerink Downgrades VectivBio Holding (VECT)

May 23, 2023 | americanbankingnews.com

VectivBio (NASDAQ:VECT) Rating Lowered to Market Perform at SVB Securities

May 23, 2023 | msn.com

Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy

May 22, 2023 | finance.yahoo.com

VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 Billion

May 22, 2023 | benzinga.com

Thinking about buying stock in Palantir Technologies, DraftKings, Micron Technology, Rain Oncology, or VectivBio?

May 22, 2023 | finance.yahoo.com

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

May 22, 2023 | finance.yahoo.com

Why Shares of VectivBio Holding Are Up Today

May 22, 2023 | news.yahoo.com

Ironwood Pharma to acquire VectivBio for $1.15 billion

May 22, 2023 | msn.com

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

May 22, 2023 | markets.businessinsider.com

Ironwood Pharma To Acquire VectivBio For $17/Shr In All-cash Deal

May 11, 2023 | americanbankingnews.com

VectivBio Holding AG (NASDAQ:VECT) Short Interest Update

May 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and VectivBio Holding (VECT)

May 10, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on VectivBio Holding (VECT)

April 25, 2023 | americanbankingnews.com

SVB Leerink Analysts Lift Earnings Estimates for VectivBio Holding AG (NASDAQ:VECT)

April 24, 2023 | americanbankingnews.com

Piper Sandler Increases VectivBio (NASDAQ:VECT) Price Target to $25.00

April 22, 2023 | marketwatch.com

Short Bowel Syndrome Market Forecast [2023-2030] | Top Key-Players in the Industry are - Merck KGaA, VectivBio AG, Ardelyx, OxThera

See More Headlines

VECT Price History

30 days | 90 days | 365 days | Advanced Chart

VECT Company Calendar

Today: 6/01/2023
Next Earnings (Estimated): 7/19/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VECT
CUSIP: N/A
CIK: 1836379
Web: vectivbio.com
Phone: 41-61-551-3030
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.33
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +47.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 9.14
Quick Ratio: 9.14

Sales & Book Value

Annual Sales: $27.34 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.27 per share
Price / Book: 2.64

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.10

Key Executives

Dr. Luca Santarelli M.D. (Age 53)
Founder, CEO & Director

Ms. Claudia D'Augusta Ph.D. (Age 52)
Chief Financial Officer

Dr. Christian Meyer M.D. (Age 55)
Ph.D., Chief Operating Officer

Dr. Alain Bernard Ph.D. (Age 65)
Chief Technology Officer

Mr. Patrick Malloy
Sr. VP of Investor Relations & Strategic Communications

Mr. Scott Applebaum (Age 55)
Chief Legal Officer & Corp. Sec.

Mr. Michael Steininger
Sr. VP & Head of HR

Mr. Kevin Harris M.B.A. (Age 51)
Chief Commercial Officer

Dr. Sarah Holland Ph.D. (Age 59)
Chief Bus. Officer

Dr. Omar Khwaja M.D. (Age 51)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VECT Stock - Frequently Asked Questions

Should I buy or sell VectivBio stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VECT shares.
View VECT analyst ratings or view top-rated stocks.
What is VectivBio's stock price forecast for 2023?: 5 equities research analysts have issued 12-month target prices for VectivBio's stock. Their VECT share price forecasts range from $18.00 to $30.00. On average, they expect the company's share price to reach $24.33 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts price targets for VECT or view top-rated stocks among Wall Street analysts.
How have VECT shares performed in 2023?: VectivBio's stock was trading at $8.6650 on January 1st, 2023. Since then, VECT stock has increased by 91.0% and is now trading at $16.55.
View the best growth stocks for 2023 here.
Are investors shorting VectivBio?: VectivBio saw a increase in short interest in May. As of May 15th, there was short interest totaling 580,300 shares, an increase of 123.5% from the April 30th total of 259,700 shares. Based on an average daily trading volume, of 574,800 shares, the short-interest ratio is currently 1.0 days. Approximately 2.1% of the company's stock are sold short.
View VectivBio's Short Interest.
When is VectivBio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our VECT earnings forecast.

When did VectivBio IPO?: (VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.
What is VectivBio's stock symbol?: VectivBio trades on the NASDAQ under the ticker symbol "VECT."
Who are VectivBio's major shareholders?: VectivBio's stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (0.00%), Tekla Capital Management LLC (0.00%), Balyasny Asset Management L.P. (0.95%), Gilder Gagnon Howe & Co. LLC (0.17%), UBS Group AG (0.16%) and Bank of America Corp DE (0.12%).
How do I buy shares of VectivBio?: Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is VectivBio's stock price today?: One share of VECT stock can currently be purchased for approximately $16.55.
How can I contact VectivBio?: The official website for the company is vectivbio.com. The company can be reached via phone at 41-61-551-3030 or via email at ir@vectivbio.com.

This page (NASDAQ:VECT) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

VectivBio (VECT) Stock Forecast, Price & News

VectivBio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About VectivBio (NASDAQ:VECT) Stock

VECT Stock News Headlines

VECT Price History

VECT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

VECT Stock - Frequently Asked Questions

Overall MarketRank^™